Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 65 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR TRACERx: Using blood tests to track lung cancer May 1, 2023 Identical Twins Get Mirror Cancer Diagnoses Within Three Weeks Of Each... August 15, 2019 Father Dances With Joy After Learning His Son Is Cancer Free November 14, 2021 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 Load more HOT NEWS Spotlight On: Occupational Therapists in Cancer Care FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease Why we need to continue to advocate for global tobacco control FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer
